Negotiations between Dutch universities and scholarly publishing giant Elsevier regarding unaffordable subscription fees and open access have ‘ground to a halt’. In other Elsevier news, two of its major brands, Cell Press and The Lancet , have joined forces to launch a new open access journal, EBioMedicine . The broad-spectrum journal will publish research papers covering the entire breadth of life and health sciences,